Related Experiment Videos
Prothionamide and dapsone therapy in leprosy--a clinical study
Indian Journal of Leprosy
|January 1, 1985
Summary
Combined therapy with prothionamide and dapsone showed good clinical improvement in lepromatous leprosy patients. However, bacteriological response was unsatisfactory, with side effects and poor prothionamide compliance noted.
Area of Science:
- Dermatology
- Infectious Diseases
- Microbiology
Background:
- Leprosy remains a significant global health challenge.
- Multidrug therapy is standard, but resistance and treatment efficacy are ongoing concerns.
Purpose of the Study:
- To evaluate the efficacy and safety of combined prothionamide and dapsone therapy.
- To assess clinical and bacteriological outcomes in untreated lepromatous leprosy.
Main Methods:
- Fifteen active untreated lepromatous leprosy patients received combined prothionamide and dapsone.
- Treatment duration was 18 months.
- Clinical and bacteriological parameters were monitored.
Main Results:
- Good clinical improvement observed in approximately 66% of cases, indicated by a zero morphological index.
- Bacteriological improvement was unsatisfactory, with only one case reaching a zero level.
- Side effects led to treatment withdrawal in some patients.
- Patient compliance with prothionamide was suboptimal.
Conclusions:
- Combined prothionamide and dapsone therapy demonstrates potential for clinical improvement in lepromatous leprosy.
- Further research is needed to address bacteriological efficacy and improve treatment compliance and tolerability.